Eric Quéméneur
Chief Tech/Sci/R&D Officer chez TRANSGENE
Profil
Eric Quéméneur is currently the Director & EVP-Research & Development at ElsaLys Biotech SAS and the Chief Scientific Officer & Executive VP at Transgene SA. Previously, he worked as the Director-Research Programs at Comité de l’énergie Atomique from 1990 to 2014.
Dr. Quéméneur holds a doctorate degree from Université Claude Bernard Lyon 1 and an undergraduate degree from Institut National des Sciences Appliquées de Lyon, which he obtained in 1986.
Postes actifs de Eric Quéméneur
| Sociétés | Poste | Début |
|---|---|---|
| TRANSGENE | Chief Tech/Sci/R&D Officer | 01/09/2014 |
| ELSALYS BIOTECH | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Eric Quéméneur
| Sociétés | Poste | Fin |
|---|---|---|
| Comité de l’énergie Atomique | Corporate Officer/Principal | 01/09/2014 |
Formation de Eric Quéméneur
| Université Claude Bernard Lyon 1 | Doctorate Degree |
| Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Comité de l’énergie Atomique | Government |
ElsaLys Biotech SAS
 ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France. | Health Technology |
